학술논문

Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors
Document Type
article
Author
Torchia, JonathonGolbourn, BrianFeng, ShengruiHo, ChingSin-Chan, PatrickVasiljevic, AlexandreNorman, Joseph DGuilhamon, PaulGarzia, LiviaAgamez, Natalia RLu, MeiChan, Tiffany SPicard, Danielde Antonellis, PasqualinoKhuong-Quang, Dong-AnhPlanello, Aline CZeller, ConstanzeBarsyte-Lovejoy, DaliaLafay-Cousin, LucieLetourneau, LouisBourgey, MathieuYu, ManGendoo, Deena MADzamba, MiskoBarszczyk, MarkMedina, TiagoRiemenschneider, Alexandra NMorrissy, A SoranaRa, Young-ShinRamaswamy, VijayRemke, MarcDunham, Christopher PYip, StephenNg, Ho-keungLu, Jian-QiangMehta, VivekAlbrecht, SteffenPimentel, JoseChan, Jennifer ASomers, Gino RFaria, Claudia CRoque, LuciaFouladi, MaryamHoffman, Lindsey MMoore, Andrew SWang, YinChoi, Seung AhHansford, Jordan RCatchpoole, DanielBirks, Diane KForeman, Nicholas KStrother, DougKlekner, AlmosBognár, LaszlóGarami, MiklósHauser, PéterHortobágyi, TiborWilson, BeverlyHukin, JulietteCarret, Anne-SophieVan Meter, Timothy EHwang, Eugene IGajjar, AmarChiou, Shih-HwaNakamura, HideoToledano, HelenFried, IrisFults, DanielWataya, TakafumiFryer, ChrisEisenstat, David DScheinemann, KatrinFleming, Adam JJohnston, Donna LMichaud, JeanZelcer, ShaynaHammond, RobertAfzal, SaminaRamsay, David ASirachainan, NongnuchHongeng, SuradejLarbcharoensub, NoppadolGrundy, Richard GLulla, Rishi RFangusaro, Jason RDruker, HarrietBartels, UteGrant, RonaldMalkin, DavidMcGlade, C JaneNicolaides, TheodoreTihan, TarikPhillips, JoannaMajewski, JacekMontpetit, AlexandreBourque, GuillaumeBader, Gary DReddy, Alyssa TGillespie, G YanceyWarmuth-Metz, Monika
Source
Cancer Cell. 30(6)
Subject
Genetics
Human Genome
Rare Diseases
Orphan Drug
Cancer
2.1 Biological and endogenous factors
Development of treatments and therapeutic interventions
Aetiology
5.1 Pharmaceuticals
Cell Line
Tumor
Cell Proliferation
Cell Survival
Central Nervous System Neoplasms
Chromatin
DNA Methylation
Dasatinib
Epigenesis
Genetic
Epigenomics
Humans
Mutation
Protein Kinase Inhibitors
Pyrimidines
Receptor
Platelet-Derived Growth Factor beta
Rhabdoid Tumor
SMARCB1 Protein
Teratoma
ATRT
enhancer
epigenomics
genomics
rhabdoid tumors
subgroup-specific therapeutics
Neurosciences
Oncology and Carcinogenesis
Oncology & Carcinogenesis
Language
Abstract
We recently reported that atypical teratoid rhabdoid tumors (ATRTs) comprise at least two transcriptional subtypes with different clinical outcomes; however, the mechanisms underlying therapeutic heterogeneity remained unclear. In this study, we analyzed 191 primary ATRTs and 10 ATRT cell lines to define the genomic and epigenomic landscape of ATRTs and identify subgroup-specific therapeutic targets. We found ATRTs segregated into three epigenetic subgroups with distinct genomic profiles, SMARCB1 genotypes, and chromatin landscape that correlated with differential cellular responses to a panel of signaling and epigenetic inhibitors. Significantly, we discovered that differential methylation of a PDGFRB-associated enhancer confers specific sensitivity of group 2 ATRT cells to dasatinib and nilotinib, and suggest that these are promising therapies for this highly lethal ATRT subtype.